News for Ribomic Inc. (4591.T)

Published at

Aug 3, 2024 4:12 PM

by investing.com

positive

positive

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study By Investing.co

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study

4591.T

Read more →
Published at

Dec 5, 2023 12:53 PM

by marketscreener.com

positive

positive

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

- Intravitreal umedaptanib pegol is safe, well tolerated, and effective in treatment naïve nAMD patients with striking improvement in some of the patients - Umedaptanib pegol is inferior to...

4591.T

Read more →
Published at

Feb 4, 2023 1:15 AM

by prnewswire.com

mixed

mixed

Age-related macular degeneration (AMD) market size to increase by USD 4,360.68 million: Evolving Opportunities with Amgen Inc and Apellis Pharmaceuticals Inc among others - Technavio

/PRNewswire/ -- Technavio report provides the key offerings of 15+ vendors of the age-related macular degeneration market. For Instance, one of the key...

VTRSV VTRS.MX VTRS VIA.DE ISEE APLS AMGN.MX AMGN.BA AMGN AMG.DE 4591.T REGN34.SA REGN.MX REGN PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE OTLK NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA ALIM ADVM ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE 0R2M.L 0K9E.L 0HA3.L

Read more →
Published at

Sep 19, 2022 7:00 PM

by globenewswire.com

mixed

mixed

Wet AMD Clinical Trials Pipeline Analysis Featuring 70+ Key Companies by DelveInsight

DelveInsight’s Wet AMD pipeline analysis depicts a robust space with 70+ active players working to develop 80+ pipeline therapies....

ISEE EYPT CLSD AERI RGNX OTLK OPT.AX OPT KOD.MX KOD CKDXF 4591.T

Read more →
Published at

Jul 25, 2022 2:40 PM

by globenewswire.com

mixed

mixed

Global Achondroplasia Market to Surpass US$ 1,100.97 Million by 2030, Says Coherent Market Insights (CMI)

seattle, July 25, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global achondroplasia market is estimated to be valued at US$ 93.82...

PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE BBIO ASND A1SN34.SA 688278.SS 4591.T PHAS NVSN.MX NVSEF NVSD.BA NVS NVON.MX NVO NOVOBN.MX NOVN.SW NOVC.DE NOVA.DE NONOF N1VS34.SA LLY.MX LLY.DE LLY.BA LLY LILY34.SA 4552.T 0TDD.L 0Q1G.L 0K9E.L

Read more →
Published at

Jun 13, 2022 5:30 PM

by prnewswire.com

mixed

mixed

Age-related Macular Degeneration Market to Progress at a CAGR of 3.4% by 2032 | DelveInsight

/PRNewswire/ -- DelveInsight's Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices,...

OTLK OPT.AX OPT CKDXF 4591.T UBX KOD.MX KOD 0YC0.L

Read more →
Published at

Jan 11, 2022 9:38 AM

by marketscreener.com

neutral

neutral

RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference

News Release RIBOMIC Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference TOKYO, January 11, 2022 -... | January 11, 2022

4591.T

Read more →
Published at

Dec 28, 2021 7:17 AM

by marketscreener.com

neutral

neutral

RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

News Release RIBOMIC Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration TOKYO,... | December 28, 2021

4591.T

Read more →
Published at

Sep 30, 2021 4:49 PM

by marketscreener.com

positive

positive

RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting

Data show a consistent safety profile and potential BCVA benefit in wAMD patients with suboptimal response to prior anti-VEGF therapy ... | September 30, 2021

4591.T

Read more →
Published at

Sep 30, 2021 8:12 AM

by marketscreener.com

mixed

mixed

RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet AMD at the Retina Society 2021 Meeting

News Release RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the... | September 30, 2021

4591.T 7374.T 4068.T

Read more →